Y Intercept Hong Kong Ltd Raises Position in Natera, Inc. (NASDAQ:NTRA)

Y Intercept Hong Kong Ltd lifted its holdings in Natera, Inc. (NASDAQ:NTRA) by 211.9% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 31,144 shares of the medical research company’s stock after purchasing an additional 21,160 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Natera were worth $4,930,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Wellington Management Group LLP raised its holdings in shares of Natera by 205.4% during the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock worth $355,493,000 after acquiring an additional 1,883,481 shares during the period. Massachusetts Financial Services Co. MA raised its stake in Natera by 3.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock worth $315,194,000 after purchasing an additional 85,236 shares during the period. Geode Capital Management LLC raised its stake in Natera by 7.4% during the third quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock worth $265,747,000 after purchasing an additional 143,825 shares during the period. Maverick Capital Ltd. raised its stake in Natera by 25.2% during the third quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company’s stock worth $170,119,000 after purchasing an additional 269,706 shares during the period. Finally, Castle Hook Partners LP raised its position in shares of Natera by 27.4% during the 3rd quarter. Castle Hook Partners LP now owns 1,140,090 shares of the medical research company’s stock valued at $144,734,000 after buying an additional 245,505 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have commented on NTRA. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. The Goldman Sachs Group boosted their price objective on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Robert W. Baird boosted their price objective on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Canaccord Genuity Group boosted their price target on shares of Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Finally, TD Cowen boosted their price target on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $170.94.

Natera Price Performance

NTRA stock opened at $162.31 on Monday. Natera, Inc. has a 1 year low of $69.74 and a 1 year high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock’s 50 day moving average price is $167.98 and its 200 day moving average price is $145.85. The firm has a market cap of $21.43 billion, a P/E ratio of -92.22 and a beta of 1.66.

Insider Activity at Natera

In other Natera news, CFO Michael Burkes Brophy sold 43,502 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $176.88, for a total value of $7,694,633.76. Following the completion of the transaction, the chief financial officer now directly owns 70,629 shares in the company, valued at approximately $12,492,857.52. The trade was a 38.12 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider John Fesko sold 663 shares of Natera stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the sale, the insider now directly owns 156,044 shares of the company’s stock, valued at approximately $27,739,941.88. This represents a 0.42 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 295,772 shares of company stock valued at $49,741,699. 7.60% of the stock is owned by corporate insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.